Merck Serono announced the appointment of Luciano Rossetti, M.D. as Executive VP and Global Head of Research & Development

Darmstadt, Germany, 17-7-2014 — /EuropaWire/ — Merck Serono, the biopharmaceutical division of Merck, today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.

In his most recent role Rossetti (57) acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD. In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas. At MSD, he played a key role in shaping and implementing the development strategy of several potential breakthrough compounds such as Anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development. Before joining MSD in 2006, Rossetti was an internationally recognized academic scientist for 18 years.

„I’m thrilled to welcome Luciano Rossetti to Merck,” said Belén Garijo, President and CEO at Merck Serono. “His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world.“

Rossetti will be based in Billerica, outside Boston, Massachusetts (U.S.), and share his time between Merck’s headquarters in Darmstadt (Germany) and Billerica – one of Merck Serono’s four global R&D hubs.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Your Contact
Gangolf Schrimpf +49 6151 72-9591
Investor Relations +49 6151 72-3321

###

Luciano Rossetti

Luciano Rossetti

Comments are closed.